April Fools is over, folks; that's not a joke. Seems we need another lesson in what a company gains from a fast-track designation.
The FDA gives fast-track designations to drugs designed to treat serious diseases that have unmet need. Colon cancer certainly counts as serious, and while there are plenty of approved treatments for it-- including Bristol-Myers Squibb
Here's what a company can get with its fast-track designation:
- Increased interaction with the FDA to discuss the drug's development, including clinical trial design.
- Eligiblility for accelerated approval using surrogate endpoints, like progression-free survival instead of overall survival.
- A rolling review, where the FDA starts reviewing sections of the New Drug Application (NDA) as they're available, rather than waiting until the entire application is complete.
You'll notice that "increased chance of approval" isn't listed. Nor is "a guarantee of higher sales." A fast-track designation may make for nice press releases, but its value is fairly limited for drugmakers.
Keryx already has a Special Protocol Assessment (SPA) with the FDA for the phase 3 trial it will begin shortly, so the first two advantages aren't too valuable at this point. The rolling review sounds good, but a fast-track designation never seems to speed up the approval process too much. Dendreon's
The bigger influence on the timing of an approval comes from whether a drug gets a standard 10-month review or a priority six-month review time frame. That decision is separate from the fast-track designation, and it isn't decided until the marketing application gets turned in. Most drugs given fast-track designation receive priority reviews, since both designations are based on the needs of patients. But the timing of the review is ultimately decided by the data in the clinical trials. Cell Therapeutics
If you agree with me that Keryx doesn't deserve a double-digit increase for gaining fast-track designation, join me in marking it as an underperform in Motley Fool CAPS. I'm hoping to ride Keryx's coattails down, if only to increase my All-Star ranking a little more.
More from The Motley Fool
Keryx Biopharma Down 17% Despite Drug Approval
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
The company's winning new customers, but that didn't help its third-quarter financials.
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
It was another down month for the small-cap biopharma, but this pending regulatory news promises to turn the company's fortunes around.